IPCA LABORATORIES: Beat on all fronts; momentum to sustain over medium term
- API/branded generics formulation-led revenue growth: Sales were up 27% YoY at INR12.8b in 2QFY20, led by strong growth in exports (branded + institutional) and API segment.
- Operating leverage more than offsets lower gross margin: Gross margin (GM) shrank 400bp YoY to 65% due to product mix change (higher share of API sales). However, EBITDA margin expanded 50bp YoY due to controlled cost (employee/other expense down 280bp/160bp YoY). EBITDA was up 30% YoY at INR2.7b (our estimate: INR2.2b), while PAT grew 30% YoY to INR2b
- Valuation and View: Positive on IPCA on the back of its superior execution in branded generics (both, domestic as well as exports) and strong momentum in API.
Disclaimer: The above report is compiled from information available on public platforms. inChat team advises users to check with certified experts before taking any investment decisions.
Found this insight useful?
Please share with your friends and family as well. You can also subscribe to one of our channels listed at the bottom of this page.